Semglee has been approved for over a year as a regular biosimilar to Lantus (insulin glargine), meaning that it could be used in place of Sanofi's drug, but only if specifically prescribed for a ...

Basaglar has been approved as a "follow-on" drug based on clinical comparisons with Lantus, the first time ... undercutting the long-acting Levemir (insulin detemir) by 21% and Tresiba (insulin ...

Prescriptions for the insulin glargine biosimilar Semglee increased after it was granted interchangeable status with its ...

Insulin glargine (Lantus; Aventis Pharmaceuticals ... These molecular changes cause the drug to precipitate upon subcutaneous injection, increasing stability and duration of action.

An essential drug that has been on the market for decades still has a sticker price out of range for some patients who need it. Insulin, a lifesaving treatment for diabetes, was first patented in ...